Products & Services

Clinical Diagnostics

Research Kits
Are you a provider of research kits looking to expand the range of your product offerings? The AD drug development market represents a large unmet need: currently announced phase 2 and 3 clinical trials will enroll some 150,000 patients (to 2010). Our assays are validated in high-throughput flow cytomtetry and ELISA formats. We seek licensees who will produce and market kits for the performance of our assays in clinical trial development programs and research.

In Vitro Diagnostics
We are proceeding with clinical diagnostic (or stand-alone diagnostic) opportunities. In order to minimize the length of the clinical trial and to maximize the returns on trial cost, the first clinical diagnostic test that we develop will be an IVD for use in MCI patient populations who do not meet current NINCDS criteria. The indication would be for a physician-administered test for the detection of AD-type dementia risk in MCI patients and would be aimed at physicians in memory clinics for clinical use.